Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | SUV39H2 | Q9H5I1 | 11/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28219652 | 1.00 | JAK3 (0.55) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL1588740 | 1.00 | JAK3 (0.55) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL15434052 | 0.94 | BTK (0.63) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL3370146 | 0.93 | CKS1B (0.59) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL1427784 | 0.91 | EIF2AK4 (0.54) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL18228315 | 0.88 | PDE10A (0.55) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL16620599 | 0.87 | MAP4K4 (0.59) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL16620602 | 0.87 | MAP4K4 (0.59) | JAK3BTKPDE10AMAP4K4SUV39H2 | |
| SCHEMBL16629154 | 0.86 | CCNC (0.62) | PDE10AMAP4K4 | |
| SCHEMBL7386934 | 0.83 | BTK (0.51) | JAK3BTKPDE10AMAP4K4SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| WO-2015049325-A1 | THERAPEUTIC INHIBITORS OF CDK8 AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | JAK3 1064/4885BTK 784/4885PDE10A 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.